Early Intensive Chemotherapy for Children with Acute Myelogenous Leukemia: The Pediatric Oncology Group Experience (1981–1991)

  • H. Weinstein
  • Y. Ravindranath
  • J. Krischer
  • C. P. Steuber
  • C. Civin
  • M. Gresik
  • T. Vietti
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 36)

Abstract

During the past decade, the Pediatric Oncology Group (POG) clinical trials for childhood acute myelogenous leukemia (AML) have focused on the early phases of treatment since the median time to relapse tends to occur within the first six to nine months after diagnosis. The POG protocols have asked both remission induction and postremission questions with an emphasis on dose intensity of cytosine arabinoside (ara-C) and ’the use of “non cross-resistant pairs of drugs” [1,2]. The most recent POG protocol (AML 8821) asked a postremission question comparing autologous bone marrow transplantation to six months of multi-agent chemotherapy that included high dose ara-C. The long term results of the POG protocols 8101 and 8498 and the preliminary results from POG 8821 are reported in this manuscript.

Keywords

Toxicity Leukemia Oncol Methotrexate Cyclophosphamide 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Steuber CP, Civin C, Krischer J et al. (1991) A comparison of induction and maintenance therapy for acute nonlymphocytic leukemia in childhood: Results of a Pediatric Oncology Group Study. J Clin Oncol 9: 247–258PubMedGoogle Scholar
  2. 2.
    Ravindranath Y, Steuber CP, Krischer J et al. (1991) High-dose cytarabine for intensification of early therapy of childhood acute myeloid leukemia: A Pediatric Oncology Group Study, J Clin Oncol 9: 572–580PubMedGoogle Scholar
  3. 3.
    Weinstein H, Mayer R, Rosenthal D et al. (1983) Chemotherapy for acute myelogenous leukemia in children and adults. VAPA update. Blood 62: 315–319PubMedGoogle Scholar
  4. 4.
    Buckley J, Chard R, Baehner R et al. (1989) Improvement in outcome for children with acute nonlymphocytic leukemia. A report from the Children’s Cancer Study Group. Cancer 63: 1457–1465PubMedCrossRefGoogle Scholar
  5. 5.
    Creutzig U, Ritter J, and Schellong G (1990) Identification of two risk groups in childhood acute myelogenous leukemia after therapy intensification in study AML-BFM-83 as compared with Study AML-BFM-78. Blood 75: 1932–1940PubMedGoogle Scholar
  6. 6.
    Kalwinsky D, Mirro J, Schell M et al. (1988) Early intensification of chemotherapy for childhood acute nonlymphoblastic leukemia improved remission induction with a five-drug regimen including etoposide. J Clin Oncol 6: 1134–1143PubMedGoogle Scholar
  7. 7.
    Wolff S, Herzig R, Fay J et al. (1989) High dose cytosine arabinoside and daunomycin as consolidation therapy for acute non-myeloid leukemia in first remission: long term results. J Clin Oncol 7: 1260–1267PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1994

Authors and Affiliations

  • H. Weinstein
    • 1
  • Y. Ravindranath
    • 1
  • J. Krischer
    • 1
  • C. P. Steuber
    • 1
  • C. Civin
    • 1
  • M. Gresik
    • 1
  • T. Vietti
    • 1
  1. 1.Dana Farber Cancer InstituteBostonUSA

Personalised recommendations